EVO100 + Placebo
Phase 2/3Completed 0 watching 0 views this week⚡ Active
57
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chlamydia Trachomatis Infection
Conditions
Chlamydia Trachomatis Infection
Trial Timeline
Nov 3, 2017 → Aug 22, 2019
NCT ID
NCT03107377About EVO100 + Placebo
EVO100 + Placebo is a phase 2/3 stage product being developed by Evofem Biosciences for Chlamydia Trachomatis Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03107377. Target conditions include Chlamydia Trachomatis Infection.
Hype Score Breakdown
Clinical
22
Activity
15
Company
2
Novelty
7
Community
8
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04553068 | Phase 3 | Completed |
| NCT03107377 | Phase 2/3 | Completed |
Competing Products
1 competing product in Chlamydia Trachomatis Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Chlamydia mRNA Vaccine | Sanofi | Phase 1/2 | 40 |